Log in

NASDAQ:YMAB - Y-mAbs Therapeutics Stock Price, Forecast & News

$32.97
-0.49 (-1.46 %)
(As of 02/17/2020 01:23 AM ET)
Add
Today's Range
$32.64
Now: $32.97
$33.56
50-Day Range
$29.89
MA: $32.65
$35.80
52-Week Range
$19.03
Now: $32.97
$36.29
Volume90,331 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:YMAB
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees32
Next Earnings Date3/27/2020 (Estimated)
OptionableNot Optionable

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.


Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) issued its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.16. View Y-mAbs Therapeutics' Earnings History.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for Y-mAbs Therapeutics.

What price target have analysts set for YMAB?

5 brokers have issued 12-month target prices for Y-mAbs Therapeutics' stock. Their forecasts range from $38.00 to $41.00. On average, they expect Y-mAbs Therapeutics' stock price to reach $39.50 in the next year. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Price Targets for Y-mAbs Therapeutics.

What is the consensus analysts' recommendation for Y-mAbs Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Y-mAbs Therapeutics.

Has Y-mAbs Therapeutics been receiving favorable news coverage?

Media headlines about YMAB stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Y-mAbs Therapeutics earned a news impact score of 2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Y-mAbs Therapeutics.

Are investors shorting Y-mAbs Therapeutics?

Y-mAbs Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,500,000 shares, a decrease of 9.1% from the January 15th total of 1,650,000 shares. Based on an average daily volume of 284,800 shares, the short-interest ratio is presently 5.3 days. Currently, 7.7% of the company's shares are short sold. View Y-mAbs Therapeutics' Current Options Chain.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the folowing people:
  • Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. (Age 48)
  • Dr. Claus Juan Møller San Pedro, CEO & Director (Age 56)
  • Mr. Bo Kruse, Exec. VP, Sec., Treasurer, CFO & Director (Age 47)
  • Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 44)
  • Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 68)

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sofinnova Investments Inc. (5.52%), FMR LLC (3.50%), State Street Corp (1.88%), Goldman Sachs Group Inc. (1.45%), Perceptive Advisors LLC (1.42%) and Loomis Sayles & Co. L P (1.37%). Company insiders that own Y-mAbs Therapeutics stock include Ashu Tyagi, James Healy, Johan Wedell-Wedellsborg, Moller San Pedro Claus Juan and Thomas Gad. View Institutional Ownership Trends for Y-mAbs Therapeutics.

Which institutional investors are selling Y-mAbs Therapeutics stock?

YMAB stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, FMR LLC, Renaissance Technologies LLC and Vident Investment Advisory LLC. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Johan Wedell-Wedellsborg and Thomas Gad. View Insider Buying and Selling for Y-mAbs Therapeutics.

Which institutional investors are buying Y-mAbs Therapeutics stock?

YMAB stock was acquired by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, State Street Corp, Goldman Sachs Group Inc., Driehaus Capital Management LLC, Sofinnova Investments Inc., Schonfeld Strategic Advisors LLC, Candriam Luxembourg S.C.A. and Rice Hall James & Associates LLC. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Ashu Tyagi, James Healy and Moller San Pedro Claus Juan. View Insider Buying and Selling for Y-mAbs Therapeutics.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $32.97.


MarketBeat Community Rating for Y-mAbs Therapeutics (NASDAQ YMAB)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  133
MarketBeat's community ratings are surveys of what our community members think about Y-mAbs Therapeutics and other stocks. Vote "Outperform" if you believe YMAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe YMAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Inverted Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel